146 related articles for article (PubMed ID: 30168243)
21. Imatinib in the treatment of chronic myeloid leukemia in children and adolescents is effective and well tolerated: Report of the Polish Pediatric Study Group for the Treatment of Leukemias and Lymphomas.
Janeczko-Czarnecka M; Krawczuk-Rybak M; Karpińska-Derda I; Niedźwiecki M; Musioł K; Ćwiklińska M; Drabko K; Mycko K; Ociepa T; Pawelec K; Januszkiewicz-Lewandowska D; Ussowicz M; Rybka B; Ryczan-Krawczyk R; Kołtan A; Karolczyk G; Zaucha-Prażmo A; Badowska W; Kałwak K
Adv Clin Exp Med; 2018 Jan; 27(1):91-98. PubMed ID: 29521048
[TBL] [Abstract][Full Text] [Related]
22. Allogeneic Hematopoietic Stem Cell Transplantation Is an Effective Salvage Therapy for Patients with Chronic Myeloid Leukemia Presenting with Advanced Disease or Failing Treatment with Tyrosine Kinase Inhibitors.
Nair AP; Barnett MJ; Broady RC; Hogge DE; Song KW; Toze CL; Nantel SH; Power MM; Sutherland HJ; Nevill TJ; Abou Mourad Y; Narayanan S; Gerrie AS; Forrest DL
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1437-44. PubMed ID: 25865648
[TBL] [Abstract][Full Text] [Related]
23. [Prognosis of children with chronic myeloid leukemia: a retrospective analysis of 75 patients].
Creutzig U; Ritter J; Zimmermann M; Klingebiel T
Klin Padiatr; 1996; 208(4):236-41. PubMed ID: 8926689
[TBL] [Abstract][Full Text] [Related]
24. [Modern therapy of chronic myeloid leukemia: an example for paradigma shift in hemato-oncology].
Leitner AA; Hehlmann R
Internist (Berl); 2011 Feb; 52(2):209-17. PubMed ID: 21225238
[TBL] [Abstract][Full Text] [Related]
25. Outcomes Following Bone Marrow Transplantation in Children With Accelerated Phase or Blast Crisis Chronic Myelogenous Leukemia in the Era of Tyrosine Kinase Inhibitors.
Shulman DS; Lee MA; Lehmann LE; Margossian SP
J Pediatr Hematol Oncol; 2016 Nov; 38(8):610-614. PubMed ID: 27403776
[TBL] [Abstract][Full Text] [Related]
26. Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment.
Gratwohl A; Pfirrmann M; Zander A; Kröger N; Beelen D; Novotny J; Nerl C; Scheid C; Spiekermann K; Mayer J; Sayer HG; Falge C; Bunjes D; Döhner H; Ganser A; Schmidt-Wolf I; Schwerdtfeger R; Baurmann H; Kuse R; Schmitz N; Wehmeier A; Fischer JT; Ho AD; Wilhelm M; Goebeler ME; Lindemann HW; Bormann M; Hertenstein B; Schlimok G; Baerlocher GM; Aul C; Pfreundschuh M; Fabian M; Staib P; Edinger M; Schatz M; Fauser A; Arnold R; Kindler T; Wulf G; Rosselet A; Hellmann A; Schäfer E; Prümmer O; Schenk M; Hasford J; Heimpel H; Hossfeld DK; Kolb HJ; Büsche G; Haferlach C; Schnittger S; Müller MC; Reiter A; Berger U; Saußele S; Hochhaus A; Hehlmann R; ;
Leukemia; 2016 Mar; 30(3):562-9. PubMed ID: 26464170
[TBL] [Abstract][Full Text] [Related]
27. Targeted chronic myeloid leukemia therapy: seeking a cure.
Fausel C
J Manag Care Pharm; 2007 Oct; 13(8 Suppl A):8-12. PubMed ID: 17970609
[TBL] [Abstract][Full Text] [Related]
28. Chronic myeloid leukemia in children: clinical findings, management, and unanswered questions.
Hijiya N; Millot F; Suttorp M
Pediatr Clin North Am; 2015 Feb; 62(1):107-19. PubMed ID: 25435115
[TBL] [Abstract][Full Text] [Related]
29. Prognostic Factors for Outcomes of Allogeneic HSCT for Children and Adolescents/Young Adults With CML in the TKI Era.
Shimada H; Tanizawa A; Kondo T; Nagamura-Inoue T; Yasui M; Tojo A; Muramatsu H; Eto T; Doki N; Tanaka M; Sato M; Noguchi M; Uchida N; Takahashi Y; Sakata N; Ichinohe T; Hashii Y; Kato K; Atsuta Y; Ohashi K;
Transplant Cell Ther; 2022 Jul; 28(7):376-389. PubMed ID: 35447373
[TBL] [Abstract][Full Text] [Related]
30. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience.
Kantarjian H; O'Brien S; Jabbour E; Garcia-Manero G; Quintas-Cardama A; Shan J; Rios MB; Ravandi F; Faderl S; Kadia T; Borthakur G; Huang X; Champlin R; Talpaz M; Cortes J
Blood; 2012 Mar; 119(9):1981-7. PubMed ID: 22228624
[TBL] [Abstract][Full Text] [Related]
31. Survival trends in childhood chronic myeloid leukaemia in Southern-Eastern Europe and the United States of America.
Karalexi MA; Baka M; Ryzhov A; Zborovskaya A; Dimitrova N; Zivkovic S; Eser S; Antunes L; Sekerija M; Zagar T; Bastos J; Demetriou A; Agius D; Florea M; Coza D; Polychronopoulou S; Stiakaki E; Moschovi M; Hatzipantelis E; Kourti M; Graphakos S; Pombo-de-Oliveira MS; Adami HO; Petridou ET
Eur J Cancer; 2016 Nov; 67():183-190. PubMed ID: 27677054
[TBL] [Abstract][Full Text] [Related]
32. Reduced-intensity allogeneic hematopoietic stem cell transplantation combined with imatinib has comparable event-free survival and overall survival to long-term imatinib treatment in young patients with chronic myeloid leukemia.
Zhao Y; Wang J; Luo Y; Shi J; Zheng W; Tan Y; Cai Z; Huang H
Ann Hematol; 2017 Aug; 96(8):1353-1360. PubMed ID: 28624905
[TBL] [Abstract][Full Text] [Related]
33. Response to tyrosine kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic stem cell transplantation.
Wright MP; Shepherd JD; Barnett MJ; Nantel SH; Sutherland HJ; Toze CL; Hogge DE; Nevill TJ; Song KW; Abou Mourad YR; Narayanan S; Power MM; Smith CA; Forrest DL
Biol Blood Marrow Transplant; 2010 May; 16(5):639-46. PubMed ID: 20005967
[TBL] [Abstract][Full Text] [Related]
34. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis.
Chaudhury S; Sparapani R; Hu ZH; Nishihori T; Abdel-Azim H; Malone A; Olsson R; Hamadani M; Daly A; Bacher U; Wirk BM; Kamble RT; Gale RP; Wood WA; Hale G; Wiernik PH; Hashmi SK; Marks D; Ustun C; Munker R; Savani BN; Alyea E; Popat U; Sobecks R; Kalaycio M; Maziarz R; Hijiya N; Saber W
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1056-1064. PubMed ID: 26964698
[TBL] [Abstract][Full Text] [Related]
35. Stem cell transplant for chronic myeloid leukemia in the imatinib era.
Radich J
Semin Hematol; 2010 Oct; 47(4):354-61. PubMed ID: 20875552
[TBL] [Abstract][Full Text] [Related]
36. Long-term follow-up of children with chronic myeloid leukemia after hematopoietic stem cell transplantation and tyrosine kinase inhibitor therapy.
Broglie L; Hijiya N; Helenowski IB; Dilley K; Schneiderman J; Tse W; Duerst R; Kletzel M; Morgan E; Chaudhury S
Leuk Lymphoma; 2016; 57(4):949-52. PubMed ID: 26694579
[No Abstract] [Full Text] [Related]
37. Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
Kantarjian H; O'Brien S; Jabbour E; Shan J; Ravandi F; Kadia T; Faderl S; Garcia-Manero G; Borthakur G; Cortes J
J Clin Oncol; 2011 Aug; 29(23):3173-8. PubMed ID: 21747082
[TBL] [Abstract][Full Text] [Related]
38. Incidence and outcome of BCR-ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors.
Etienne G; Dulucq S; Huguet F; Schmitt A; Lascaux A; Hayette S; Fort MP; Sujobert P; Bijou F; Morisset S; Tavitian S; Bidet A; Turcq B; Robbesyn F; Chollet C; Belloc F; Durrieu F; Mahon FX; Nicolini FE
Cancer Med; 2019 Sep; 8(11):5173-5182. PubMed ID: 31350815
[TBL] [Abstract][Full Text] [Related]
39. Features and outcome of chronic myeloid leukemia at very young age: Data from the International Pediatric Chronic Myeloid Leukemia Registry.
Meral Günes A; Millot F; Kalwak K; Lausen B; Sedlacek P; Versluys AB; Dworzak M; De Moerloose B; Suttorp M
Pediatr Blood Cancer; 2021 Jan; 68(1):e28706. PubMed ID: 33034135
[TBL] [Abstract][Full Text] [Related]
40. Targeted chronic myeloid leukemia therapy: Seeking a cure.
Fausel C
Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S9-15. PubMed ID: 18056932
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
